EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Federico Marighetti

Work experience

1. Employer: University of Bonn
   - Start date: 052007
   - End date: 102013
   - Position: Research Assistant
   - Activities:
   - Country: Germany
2. Employer: Pharmacy
   - Start date: 012014
   - End date: 072016
   - Position: Pharmacist
   - Activities:
   - Country: Germany
3. Employer: Federal Institute for Drugs and Medical Devices (BfArM)
   - Start date: 082016
   - End date:
   - Position: Quality Assessor
   - Activities:
   - Country: Germany

Education and training

1. Subject: University of Bonn
   - Start date: 052007
   - End date: 102013
   - Qualification: PhD Student
   - Organisation: Title of the thesis: "Investigation of BCRP_inhibitors using QSAR and Machine Learning methods". Skills covered: Molecular modeling (2D_QSAR and 3D_QSAR, data mining), cellular assay.
   - Country: Germany
2. Subject: University of Padua
   - Start date: 091999
   - End date: 072005
   - Qualification: Master Degree in Pharmaceutical Chemistry and Technology
   - Organisation:
   - Country: Italy
3. Subject: University of Cologne
   - Start date: 042006
   - End date: 032007
   - Qualification: Postgraduate in Bioinformatics
   - Organisation: Skills covered: Computer programming, implementation of molecular descriptors.
   - Country: Germany

Additional information

Publications

_ Scaffold identification of a new class of potent and selective BCRP inhibitors. Marighetti F, Steggemann K, Karbaum M, Wiese M. ChemMedChem. 2015 Apr;10(4):742_51. doi: 10.1002/cmdc.201402498. Epub 2015 Mar 3. _ Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P_glycoprotein. Pajeva IK, Sterz K, Christlieb M, Steggemann K, Marighetti F, Wiese M. ChemMedChem. 2013 Oct;8(10):1701_13. doi: 10.1002/cmdc.201300233. Epub 2013 Aug 13. _ Synthesis and quantitative structure_activity relationships of selective BCRP inhibitors. Marighetti F, Steggemann K, Hanl M, Wiese M. ChemMedChem. 2013 Jan;8(1):125_35. doi: 10.1002/cmdc.201200377. Epub 2012 Nov 13. _ 4_amido_2_aryl_1,2,4_triazolo[4,3_a]quinoxalin_1_ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand_receptor modeling studies. Lenzi O, Colotta V, Catarzi D, Varano F, Filacchioni G, Martini C, Trincavelli L, Ciampi O, Varani K, Marighetti F, Morizzo E, Moro S. J Med Chem. 2006 Jun 29;49(13):3916_25.

Projects

Memberships

Other Relevant Information